Quick Answer
Contineum Therapeutics, Inc. reported Research And Development Expense of $51.52 million for the year ending 2025.
- Contineum Therapeutics, Inc. showed an increase of +34.1% in Research And Development Expense from 2024 to 2025.
- This data is from Contineum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $3.63 million | Q2 2023: $9.46 million | Q3 2023: $6.50 million | Q1 2024: $7.78 million | Q2 2024: $7.90 million | Q3 2024: $9.73 million | Q1 2025: $13.71 million | Q2 2025: $14.06 million | Q3 2025: $10.99 million.
- Over the full 3 years of available data (2023 to 2025), Contineum Therapeutics, Inc.'s Research And Development Expense has grown by 86.7%.
- Historical annual values: Fiscal year 2025: $51.52 million | Fiscal year 2024: $38.42 million | Fiscal year 2023: $27.60 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: